SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MEDX ... anybody following?
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2240 62 0 MEDX
Emcee:  Ed Offstein Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1940[Discussion of the results seen in the melanoma study (from the referenced PNAS Icebrg-2/20/2008
1939Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-Icebrg-2/20/2008
1938Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian Icebrg-2/20/2008
1937Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infecIcebrg-2/20/2008
1936Genes Dev. 2008 Feb 7 [Epub ahead of print] Identification of a PTEN-regulated scaram(o)uche-2/18/2008
1935Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for PsoriIcebrg-2/14/2008
1934The PD-1/PD-L costimulatory pathway critically affects host resistance to the paIcebrg-2/14/2008
1933Memorial Sloan-Kettering Cancer Center: Major Trends in Modern Cancer Research Icebrg-2/10/2008
1932Man from India talks about brain tumor Carrie Sturrock, Chronicle Staff Writer FIcebrg-2/9/2008
1931Item 5.02. Departure of Directors or Certain Officers; Election of Directors; ApIcebrg-2/7/2008
1930Item 5.02. Departure of Directors or Certain Officers; Election of Directors; ApIcebrg-2/5/2008
1929Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaquscaram(o)uche-2/2/2008
1928Genmab A/S Major shareholder announcements Major Shareholder Announcement SummaIcebrg-1/30/2008
1927Genmab Shares Fall Most Since August as Medarex Sells Stake By Frances SchwartzIcebrg-1/29/2008
1926Icahn brewing a new proxy at Biogen Idec Biogen Idec Inc., which failed to drumIcebrg-1/29/2008
1925Item 5.02 Departure of Directors or Certain Officers; Election of Directors; AppIcebrg-1/24/2008
1924Biomarker could lead to new treatment for cancer and Crohn's disease 26 DIcebrg-1/18/2008
1923The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoIcebrg-1/18/2008
1922Looks like the very last of "Cytel" has died. So, now we know..... scaram(o)uche-1/16/2008
1921IDM expects to cut workforce by 60 %. Message 24217801 There cannot be much leIcebrg-1/16/2008
1920Medarex Announces Allowance of Investigational New Drug Application for Wholly OIcebrg-1/8/2008
1919Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIIcebrg-1/7/2008
1918IDM Pharma Announces Termination of UVIDEM Development Collaboration and ExpecteIcebrg-1/1/2008
1917Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab Friday DIcebrg-12/25/2007
1916Even less need then for Medarex to add a top-up to the deferred compensation. EIcebrg-12/19/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News